Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Escalation in Young Adult ENDS Users
University of Georgia · NCT05447325
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–29 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 180
- US sites recruiting
- 1
- Study start
- July 15, 2022
- Record last updated
- April 3, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
180 young adult vapers who are not current smokers will participate in a baseline functional magnetic resonance imaging (fMRI) experiment, prospectively linked to a 1-year randomized controlled trial. Baseline fMRI tasks will probe critical neurocognitive markers with high potential to account for individual differences in nicotine use prognosis and responsiveness to anti-vaping public service announcements (PSAs). Participants will be assigned randomly to a survey-only control condition, or one of two intervention orders, Regular PSA then Flavor PSA, and Flavor PSA then Regular PSA (n=60 each) in a 1-year counterbalanced crossover design. Every week intervention groups will receive anti-vaping PSAs either do not specifically address harms associated with vaping flavors (regular PSAs) or PSAs with a theme focusing on the harms of flavored vape products (flavor PSAs). Participants of the intervention groups will switch PSA exposure condition after 6 months. Their evaluations of the PSAs will be assessed with brief weekly online surveys. The links to the weekly online surveys will be sent via e-mail and text which allow them to access the surveys using any device with an internet browser. During the survey, the PSA of that week will first be displayed to PSA groups (n=120), followed by a query to provide message evaluation. Afterward, the survey questions will also assess their e-cigarette, cigarette, other tobacco use, and nicotine dependence, during the past week. The control group (n=60) will complete the surveys without viewing PSAs. In-person assessments at 3, 6, 9, and 12 months will biochemically confirm nicotine exposure.
Being studied: Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes); Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes); Exposure to Anti-Vaping Messages (no message exposure)
Conditions: Message Exposure (Sequence: Regular Then Flavor); Message Exposure (Sequence: Flavor Then Regular); No Message Exposure (Control Condition)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- used e-cigarettes or other vaping devices at least 3 days during the past 30 days
- did not smoke a cigarette, even one or two puffs, during the past 30 days
- Magnetic resonance imaging (MRI) compatible and safe
Exclusion Criteria
- used e-cigarettes or other vaping devices for less than 3 days during the past 30 days
- any use of cigarettes during the past 30 days
- history of a major neurological, psychiatric, or medical disorder
- MRI contraindications
Recruiting US locations
UGA Bio-imaging Research Center
Athens, GA 30602
Site contact: Kim Mason · kmason@uga.edu
Study contacts (from the official record)
- Jiaying Liu, PhD · 949-241-0652 · jiaying.liu@uga.edu
Similar studies in Georgia
All smoking & vaping studies in Georgia →- RecruitingHealthy volunteers
A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an Electronic Nicotine Delivery System
RAI Services Company
- Location
- Atlanta, GA + 4 other US sites
- Eligibility basics
- Ages 21–65
- RecruitingHealthy volunteers
A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers
RAI Services Company
- Location
- Atlanta, GA + 6 other US sites
- Eligibility basics
- Ages 21–65
- RecruitingPhase 3
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
Axsome Therapeutics, Inc.
- Location
- Columbus, GA + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
Eli Lilly and Company
- Location
- Woodstock, GA + 16 other US sites
- Eligibility basics
- Ages 18–75